| Year |
Citation |
Score |
| 2023 |
Chang YS, Gills JJ, Kawabata S, Onozawa M, Della Gatta G, Ferrando AA, Aplan PD, Dennis PA. Inhibition of the NOTCH and mTOR pathways by nelfinavir as a novel treatment for T cell acute lymphoblastic leukemia. International Journal of Oncology. 63. PMID 37800623 DOI: 10.3892/ijo.2023.5576 |
0.338 |
|
| 2021 |
Ouwens M, Darilay A, Zhang Y, Mukhopadhyay P, Mann H, Ryan J, Dennis PA. Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non-Small Cell Lung Cancer from the PACIFIC Study. Current Therapeutic Research, Clinical and Experimental. 95: 100640. PMID 34484473 DOI: 10.1016/j.curtheres.2021.100640 |
0.393 |
|
| 2021 |
Socinski MA, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Gray JE, Park K, Vincent M, Mann H, Newton M, Dennis PA, Antonia SJ. Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC). Clinical Lung Cancer. PMID 34294595 DOI: 10.1016/j.cllc.2021.05.009 |
0.332 |
|
| 2021 |
Kawabata S, Connis N, Gills JJ, Hann CL, Dennis PA. Nelfinavir Inhibits the Growth of Small-cell Lung Cancer Cells and Patient-derived Xenograft Tumors. Anticancer Research. 41: 91-99. PMID 33419802 DOI: 10.21873/anticanres.14754 |
0.475 |
|
| 2021 |
Lopiccolo J, Kawabata S, Gills JJ, Dennis PA. Combining Nelfinavir With Chloroquine Inhibits Growth of Human Lung Cancer Xenograft Tumors. In Vivo (Athens, Greece). 35: 141-145. PMID 33402459 DOI: 10.21873/invivo.12241 |
0.371 |
|
| 2019 |
Hui R, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Gray JE, Rydén A, Viviers L, Poole L, ... ... Dennis PA, et al. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. The Lancet. Oncology. PMID 31601496 DOI: 10.1016/S1470-2045(19)30519-4 |
0.366 |
|
| 2019 |
Komiya T, Memmott RM, Blumenthal GM, Bernstein W, Ballas MS, De Chowdhury R, Chun G, Peer CJ, Figg WD, Liewehr DJ, Steinberg SM, Giaccone G, Szabo E, Kawabata S, Tsurutani J, ... ... Dennis PA, et al. A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer. Translational Lung Cancer Research. 8: 247-257. PMID 31367538 DOI: 10.21037/Tlcr.2019.04.19 |
0.479 |
|
| 2019 |
Sridhar S, Paz-Ares L, Liu H, Shen K, Morehouse C, Rizvi N, Segal NH, Jin X, Zheng Y, Narwal R, Gupta A, Dennis PA, Ye J, Mukhopadhyay P, Higgs BW, et al. Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients. Clinical Lung Cancer. PMID 31327642 DOI: 10.1016/j.cllc.2019.06.020 |
0.359 |
|
| 2019 |
Raben D, Rimner A, Senan S, Broadhurst H, Pellas T, Dennis P, Faivre-Finn C. Patterns of Disease Progression with Durvalumab in Stage III Non-small Cell Lung Cancer (PACIFIC) International Journal of Radiation Oncology*Biology*Physics. 105: 683. DOI: 10.1016/j.ijrobp.2019.08.034 |
0.382 |
|
| 2018 |
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, ... ... Dennis PA, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. The New England Journal of Medicine. PMID 30280658 DOI: 10.1056/NEJMoa1809697 |
0.328 |
|
| 2018 |
Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Huang Y, ... ... Dennis PA, et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. The Lancet. Oncology. PMID 29545095 DOI: 10.1016/S1470-2045(18)30144-X |
0.396 |
|
| 2018 |
Rydén A, Ollis S, Love E, Shields A, Jiang H, Dennis P. 80P Understanding the patient perspective of small cell lung cancer (SCLC) Journal of Thoracic Oncology. 13: S44. DOI: 10.1016/S1556-0864(18)30355-1 |
0.393 |
|
| 2017 |
Osoegawa A, Gills JJ, Kawabata S, Dennis PA. Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib. Oncotarget. 8: 87044-87053. PMID 29152062 DOI: 10.18632/oncotarget.19667 |
0.393 |
|
| 2017 |
Antonia S, Villegas A, Daniel D, Baz DV, Murakami S, Hui R, Yokoi T, Chiappori A, Lee K, de Wit M, Cho B, Bourhaba M, Quantin X, Tokito T, Mekhail T, ... ... Dennis P, et al. PACIFIC: A Double-Blind, Placebo-Controlled Phase 3 Study of Durvalumab as Consolidation Therapy After Chemoradiation in Patients with Locally Advanced, Unresectable Non–Small Cell Lung Cancer International Journal of Radiation Oncology*Biology*Physics. 99: 1314-1315. DOI: 10.1016/J.IJROBP.2017.09.011 |
0.361 |
|
| 2015 |
Lastwika KJ, Wilson W, Li QK, Norris J, Xu H, Ghazarian SR, Kitagawa H, Kawabata S, Taube JM, Yao S, Liu LN, Gills JJ, Dennis PA. Control of PD-L1 expression by oncogenic activation of the AKT/mTOR pathway in non-small cell lung cancer. Cancer Research. PMID 26637667 DOI: 10.1158/0008-5472.Can-14-3362 |
0.355 |
|
| 2014 |
Kawabata S, Mercado-Matos JR, Hollander MC, Donahue D, Wilson W, Regales L, Butaney M, Pao W, Wong KK, Jänne PA, Dennis PA. Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M. Cell Reports. 7: 1824-32. PMID 24931608 DOI: 10.1016/J.Celrep.2014.05.039 |
0.447 |
|
| 2014 |
Dogan I, Kawabata S, Bergbower E, Gills JJ, Ekmekci A, Wilson W, Rudin CM, Dennis PA. SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines. Lung Cancer (Amsterdam, Netherlands). 85: 1-6. PMID 24746758 DOI: 10.1016/j.lungcan.2014.03.021 |
0.397 |
|
| 2014 |
Shtivelman E, Hensing T, Simon GR, Dennis PA, Otterson GA, Bueno R, Salgia R. Molecular pathways and therapeutic targets in lung cancer. Oncotarget. 5: 1392-433. PMID 24722523 DOI: 10.18632/Oncotarget.1891 |
0.432 |
|
| 2014 |
Kawabata S, Chiang CT, Tsurutani J, Shiga H, Arwood ML, Komiya T, Gills JJ, Memmott RM, Dennis PA. Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer. Oncotarget. 5: 1062-70. PMID 24658085 DOI: 10.18632/oncotarget.1760 |
0.548 |
|
| 2013 |
Quinn BJ, Dallos M, Kitagawa H, Kunnumakkara AB, Memmott RM, Hollander MC, Gills JJ, Dennis PA. Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling. Cancer Prevention Research (Philadelphia, Pa.). 6: 801-10. PMID 23771523 DOI: 10.1158/1940-6207.Capr-13-0058-T |
0.396 |
|
| 2013 |
Lastwika K, Wilson W, Dennis PA. Abstract 4981: PI3K/AKT/mTOR pathway activation drives expression of the immune inhibitory ligand PD-L1 in NSCLC. Cancer Research. 73: 4981-4981. DOI: 10.1158/1538-7445.Am2013-4981 |
0.319 |
|
| 2013 |
Kitagawa H, Dallos M, Quinn B, Kunnumakkara A, Dogan I, Hollander CM, Dennis PA. Abstract 2269: Metformin prolongs survival in a K-rasLA2 lung cancer mouse model by inhibiting cancer stem cells and tumor growth. Cancer Research. 73: 2269-2269. DOI: 10.1158/1538-7445.Am2013-2269 |
0.403 |
|
| 2012 |
Kawabata S, Gills JJ, Mercado-Matos JR, Lopiccolo J, Wilson W, Hollander MC, Dennis PA. Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells. Cell Death & Disease. 3: e353. PMID 22825471 DOI: 10.1038/cddis.2012.87 |
0.357 |
|
| 2012 |
Gills JJ, Zhang C, Abu-Asab MS, Castillo SS, Marceau C, LoPiccolo J, Kozikowski AP, Tsokos M, Goldkorn T, Dennis PA. Ceramide mediates nanovesicle shedding and cell death in response to phosphatidylinositol ether lipid analogs and perifosine Cell Death and Disease. 3. PMID 22764099 DOI: 10.1038/Cddis.2012.72 |
0.412 |
|
| 2012 |
West L, Vidwans SJ, Campbell NP, Shrager J, Simon GR, Bueno R, Dennis PA, Otterson GA, Salgia R. A novel classification of lung cancer into molecular subtypes. Plos One. 7: e31906. PMID 22363766 DOI: 10.1371/Journal.Pone.0031906 |
0.396 |
|
| 2012 |
Quinn BJ, Dallos M, Kitagawa H, Kunnumakkara AB, Memmott RM, Gills JJ, Hollander MC, Dennis PA. Abstract PR-01: Systemic inhibition of receptor tyrosine kinase signaling by metformin Cancer Prevention Research. 5: PR-01-PR-01. DOI: 10.1158/1940-6207.Prev-12-Pr-01 |
0.396 |
|
| 2011 |
Maier CR, Hollander MC, Hobbs EA, Dogan I, Linnoila RI, Dennis PA. Nicotine does not enhance tumorigenesis in mutant K-ras-driven mouse models of lung cancer. Cancer Prevention Research (Philadelphia, Pa.). 4: 1743-51. PMID 22027685 DOI: 10.1158/1940-6207.CAPR-11-0365 |
0.409 |
|
| 2011 |
Zhang C, Elkahloun AG, Robertson M, Gills JJ, Tsurutani J, Shih JH, Fukuoka J, Hollander MC, Harris CC, Travis WD, Jen J, Dennis PA. Loss of cytoplasmic CDK1 predicts poor survival in human lung cancer and confers chemotherapeutic resistance. Plos One. 6: e23849. PMID 21887332 DOI: 10.1371/journal.pone.0023849 |
0.552 |
|
| 2011 |
Hollander MC, Zhou X, Maier CR, Patterson AD, Ding X, Dennis PA. A Cyp2a polymorphism predicts susceptibility to NNK-induced lung tumorigenesis in mice. Carcinogenesis. 32: 1279-84. PMID 21625009 DOI: 10.1093/Carcin/Bgr097 |
0.388 |
|
| 2011 |
Zhang C, Elkahloun AG, Liao H, Delaney S, Saber B, Morrow B, Prendergast GC, Hollander MC, Gills JJ, Dennis PA. Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells. Molecular Cancer Therapeutics. 10: 1137-48. PMID 21551261 DOI: 10.1158/1535-7163.Mct-10-1028 |
0.464 |
|
| 2011 |
Hollander MC, Maier CR, Hobbs EA, Ashmore AR, Linnoila RI, Dennis PA. Akt1 deletion prevents lung tumorigenesis by mutant K-ras. Oncogene. 30: 1812-21. PMID 21242979 DOI: 10.1038/onc.2010.556 |
0.409 |
|
| 2011 |
Gills JJ, Zhang C, Abu-Asab MS, Castillo SS, Marceau C, Kozikowski A, Tsokos M, Goldkorn T, Dennis PA. Abstract 960: Ceramide-dependent release of nanovesicles is a class effect oflipid-based Akt inhibitors Cancer Research. 71: 960-960. DOI: 10.1158/1538-7445.Am2011-960 |
0.348 |
|
| 2011 |
Kawabata S, Mercado J, Hollander MC, Wilson W, Regales L, Pao W, Janne PA, Wong K, Dennis PA. Abstract 2836: Rapamycin prolongs overall survival and progression-free survival in a mouse model of lung cancer in never smokers resistant to erlotinib Cancer Research. 71: 2836-2836. DOI: 10.1158/1538-7445.Am2011-2836 |
0.49 |
|
| 2011 |
Kawabata S, Hollander MC, Munasinghe JP, Mercado J, Brinster LR, Butman JA, Lonser RR, Regales L, Pao W, Janne PA, Wong K, Dennis PA. Abstract 2417: A new mouse model for epithelial ear neoplasms based upon expression of mutant EGFRL858R/T790M Cancer Research. 71: 2417-2417. DOI: 10.1158/1538-7445.Am2011-2417 |
0.338 |
|
| 2010 |
Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, Dennis PA. Metformin prevents tobacco carcinogen--induced lung tumorigenesis. Cancer Prevention Research (Philadelphia, Pa.). 3: 1066-76. PMID 20810672 DOI: 10.1158/1940-6207.CAPR-10-0055 |
0.478 |
|
| 2010 |
Memmott RM, Dennis PA. The role of the Akt/mTOR pathway in tobacco carcinogen-induced lung tumorigenesis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4-10. PMID 20028747 DOI: 10.1158/1078-0432.CCR-09-0234 |
0.527 |
|
| 2010 |
Gills JJ, Morrow B, Kawabata S, Mercado J, Hennessy B, Kunnumakkara AB, Pao W, Dennis PA. Abstract 624: Synergistic effects of combining the Akt inhibitor triciribine with erlotinib in EGFR TKI-resistant NSCLC Cancer Research. 70: 624-624. DOI: 10.1158/1538-7445.Am10-624 |
0.428 |
|
| 2009 |
Han W, Gills JJ, Memmott RM, Lam S, Dennis PA. The chemopreventive agent myoinositol inhibits Akt and extracellular signal-regulated kinase in bronchial lesions from heavy smokers. Cancer Prevention Research (Philadelphia, Pa.). 2: 370-6. PMID 19336734 DOI: 10.1158/1940-6207.CAPR-08-0209 |
0.338 |
|
| 2009 |
Granville CA, Memmott RM, Balogh A, Mariotti J, Kawabata S, Han W, Lopiccolo J, Foley J, Liewehr DJ, Steinberg SM, Fowler DH, Hollander MC, Dennis PA. A central role for Foxp3+ regulatory T cells in K-Ras-driven lung tumorigenesis. Plos One. 4: e5061. PMID 19330036 DOI: 10.1371/journal.pone.0005061 |
0.324 |
|
| 2009 |
Gills JJ, Dennis PA. Perifosine: update on a novel Akt inhibitor. Current Oncology Reports. 11: 102-10. PMID 19216841 DOI: 10.1007/s11912-009-0016-4 |
0.406 |
|
| 2009 |
Memmott RM, Dennis PA. Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cellular Signalling. 21: 656-64. PMID 19166931 DOI: 10.1016/j.cellsig.2009.01.004 |
0.379 |
|
| 2008 |
Memmott RM, Gills JJ, Hollingshead M, Powers MC, Chen Z, Kemp B, Kozikowski A, Dennis PA. Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells. Cancer Research. 68: 580-8. PMID 18199555 DOI: 10.1158/0008-5472.CAN-07-3091 |
0.476 |
|
| 2008 |
LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 11: 32-50. PMID 18166498 DOI: 10.1016/j.drup.2007.11.003 |
0.382 |
|
| 2008 |
Gills JJ, Lopiccolo J, Dennis PA. Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy. Autophagy. 4: 107-9. PMID 18000394 DOI: 10.4161/auto.5224 |
0.343 |
|
| 2007 |
LoPiccolo J, Granville CA, Gills JJ, Dennis PA. Targeting Akt in cancer therapy. Anti-Cancer Drugs. 18: 861-74. PMID 17667591 DOI: 10.1097/CAD.0b013e3280cc2c6f |
0.415 |
|
| 2007 |
Gills JJ, Castillo SS, Zhang C, Petukhov PA, Memmott RM, Hollingshead M, Warfel N, Han J, Kozikowski AP, Dennis PA. Phosphatidylinositol ether lipid analogues that inhibit AKT also independently activate the stress kinase, p38α, through MKK3/6-independent and -dependent mechanisms Journal of Biological Chemistry. 282: 27020-27029. PMID 17631503 DOI: 10.1074/Jbc.M701108200 |
0.37 |
|
| 2007 |
Granville CA, Warfel N, Tsurutani J, Hollander MC, Robertson M, Fox SD, Veenstra TD, Issaq HJ, Linnoila RI, Dennis PA. Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2281-9. PMID 17404113 DOI: 10.1158/1078-0432.Ccr-06-2570 |
0.458 |
|
| 2007 |
Lipkowitz S, Dennis PA. PPARγ agonists follow an unknown TRAIL in lung cancer Cancer Biology and Therapy. 6: 107-109. PMID 17224637 |
0.394 |
|
| 2007 |
Tsurutani J, Steinberg SM, Ballas M, Robertson M, LoPiccolo J, Soda H, Kohno S, Egilsson V, Dennis PA. Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma. Lung Cancer (Amsterdam, Netherlands). 55: 115-21. PMID 17097759 DOI: 10.1016/j.lungcan.2006.09.026 |
0.356 |
|
| 2007 |
Dennis PA, Kastan MB. Cellular survival pathways and resistance to cancer therapy. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 1: 301-9. PMID 17092811 DOI: 10.1016/S1368-7646(98)80046-0 |
0.311 |
|
| 2006 |
Warfel NA, Lepper ER, Zhang C, Figg WD, Dennis PA. Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 3502-9. PMID 16740776 DOI: 10.1158/1078-0432.Ccr-05-1837 |
0.33 |
|
| 2006 |
Gills JJ, Holbeck S, Hollingshead M, Hewitt SM, Kozikowski AP, Dennis PA. Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt Molecular Cancer Therapeutics. 5: 713-722. PMID 16546986 DOI: 10.1158/1535-7163.Mct-05-0484 |
0.414 |
|
| 2006 |
Granville CA, Memmott RM, Gills JJ, Dennis PA. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 679-89. PMID 16467077 DOI: 10.1158/1078-0432.CCR-05-1654 |
0.371 |
|
| 2006 |
Tsurutani J, Ballas M, Steinberg SM, Egilsson V, Dennis PA. Gefitinib for refractory advanced non-small-cell lung cancer. Lancet (London, England). 367: 300. PMID 16443034 DOI: 10.1016/S0140-6736(06)68064-1 |
0.445 |
|
| 2006 |
Tsurutani J, Fukuoka J, Tsurutani H, Shih JH, Hewitt SM, Travis WD, Jen J, Dennis PA. Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors Journal of Clinical Oncology. 24: 306-314. PMID 16330671 DOI: 10.1200/JCO.2005.02.4133 |
0.414 |
|
| 2005 |
Ballas MS, Dennis PA. A slow disengagement from platinum-based chemotherapy for patients with advanced non-small cell lung cancer. Cancer Biology & Therapy. 4: 1316-7. PMID 16434876 DOI: 10.4161/cbt.4.12.2488 |
0.427 |
|
| 2005 |
Tsurutani J, West KA, Sayyah J, Gills JJ, Dennis PA. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Research. 65: 8423-32. PMID 16166321 DOI: 10.1158/0008-5472.Can-05-0058 |
0.431 |
|
| 2005 |
Tsurutani J, Castillo SS, Brognard J, Granville CA, Zhang C, Gills JJ, Sayyah J, Dennis PA. Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells. Carcinogenesis. 26: 1182-95. PMID 15790591 DOI: 10.1093/Carcin/Bgi072 |
0.461 |
|
| 2005 |
Li Z, Jaboin J, Dennis PA, Thiele CJ. Genetic and pharmacologic identification of Akt as a mediator of brain-derived neurotrophic factor/TrkB rescue of neuroblastoma cells from chemotherapy-induced cell death Cancer Research. 65: 2070-2075. PMID 15781614 DOI: 10.1158/0008-5472.CAN-04-3606 |
0.378 |
|
| 2005 |
Granville CA, Dennis PA. An overview of lung cancer genomics and proteomics. American Journal of Respiratory Cell and Molecular Biology. 32: 169-76. PMID 15713815 DOI: 10.1165/rcmb.F290 |
0.394 |
|
| 2004 |
Tsurutani J, Dennis PA. Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. Journal of the National Cancer Institute. 96: 1795; author reply 1. PMID 15572763 DOI: 10.1093/jnci/djh342 |
0.469 |
|
| 2004 |
Gills JJ, Dennis PA. The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, Akt. Expert Opinion On Investigational Drugs. 13: 787-97. PMID 15212619 DOI: 10.1517/13543784.13.7.787 |
0.351 |
|
| 2004 |
West KA, Linnoila IR, Brognard J, Belinsky S, Harris C, Dennis PA. Tobacco carcinogen-induced cellular transformation increases Akt activation in vitro and in vivo. Chest. 125: 101S-2S. PMID 15136436 DOI: 10.1378/Chest.125.5_Suppl.101S |
0.468 |
|
| 2004 |
Castillo SS, Brognard J, Petukhov PA, Zhang C, Tsurutani J, Granville CA, Li M, Jung M, West KA, Gills JG, Kozikowski AP, Dennis PA. Preferential Inhibition of Akt and Killing of Akt-Dependent Cancer Cells by Rationally Designed Phosphatidylinositol Ether Lipid Analogues Cancer Research. 64: 2782-2792. PMID 15087394 DOI: 10.1158/0008-5472.Can-03-1530 |
0.366 |
|
| 2004 |
Gills JJ, Granville CA, Dennis PA. Targeting aberrant signal transduction pathways in lung cancer. Cancer Biology & Therapy. 3: 147-55. PMID 14764993 DOI: 10.4161/cbt.3.2.612 |
0.453 |
|
| 2004 |
West KA, Linnoila IR, Belinsky SA, Harris CC, Dennis PA. Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3'-kinase/Akt pathway in vitro and in vivo. Cancer Research. 64: 446-51. PMID 14744754 DOI: 10.1158/0008-5472.CAN-03-3241 |
0.587 |
|
| 2003 |
Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, Tsurutani J, Dennis PA, Mills GB, Arteaga CL. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene. 22: 2812-22. PMID 12743604 DOI: 10.1038/Sj.Onc.1206388 |
0.388 |
|
| 2003 |
Clark AS, West KA, Blumberg PM, Dennis PA. Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance. Cancer Research. 63: 780-6. PMID 12591726 |
0.513 |
|
| 2003 |
Kozikowski AP, Sun H, Brognard J, Dennis PA. Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt Journal of the American Chemical Society. 125: 1144-1145. PMID 12553797 DOI: 10.1021/Ja0285159 |
0.35 |
|
| 2003 |
West KA, Brognard J, Clark AS, Linnoila IR, Yang X, Swain SM, Harris C, Belinsky S, Dennis PA. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. The Journal of Clinical Investigation. 111: 81-90. PMID 12511591 DOI: 10.1172/Jci16147 |
0.538 |
|
| 2002 |
West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 5: 234-48. PMID 12531180 DOI: 10.1016/S1368-7646(02)00120-6 |
0.4 |
|
| 2002 |
Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Molecular Cancer Therapeutics. 1: 707-17. PMID 12479367 |
0.367 |
|
| Show low-probability matches. |